Nick van Dijk

Since January 2017, I work in the Michiel van der Heijden group as a MD/PhD on improving immunotherapy in urothelial cancer.

My goal is to better understand immune-inhibitory processes in the tumor-microenvironment to optimize immunotherapy treatment and improve patient outcome.